Please select the option that best describes you:
How do you sequence adjuvant abemaciclib and adjuvant olaparib in a patient with BRCA positive breast cancer patient with residual disease after neoadjuvant chemotherapy?
In general, and specifically in a patient with node-positive, ER/PR +, Her2 negative breast cancer with residual disease after neoadjuvant dd AC -T